GlassScriptPhysician profile
Antonio A Armstrong
NPI 1235472705
$4,945.60
in general payments reported to CMS, 2019-2025
28 companies · $981 in 2025
The $981 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.67 · 2020: $674 · 2021: $617 · 2022: $810 · 2023: $921 · 2024: $854 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.14 |
| Education | $196.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $873.07 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $705.25 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $426.50 | 2020-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $408.12 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $359.85 | 2020-2025 | Jynarque |
| Horizon Therapeutics Plc | $342.56 | 2020-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.20 | 2022-2025 | Jardiance |
| Vifor Pharma, INC. | $243.86 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $196.98 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $139.30 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $121.93 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $115.98 | 2021-2024 | Velphoro |
| Glaxosmithkline, LLC. | $112.31 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Alexion Pharmaceuticals, INC. | $91.33 | 2021-2023 | Ultomiris |
| Scpharmaceuticals INC. | $78.52 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $69.98 | 2021-2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $67.79 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.35 | 2022-2023 | Gattex |
| Lilly USA, LLC | $53.55 | 2023-2025 | Jardiance |
| Pfizer INC. | $30.61 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $30.05 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $29.88 | 2025 | Givlaari |
| Cycle Pharmaceuticals INC | $21.28 | 2024 | Tiopronin |
| Xeris Pharmaceuticals, INC. | $20.25 | 2025 | Keveyis |
| Shield Therapeutics INC | $20.24 | 2022 | |
| Gilead Sciences, INC. | $16.45 | 2025 | |
| Akebia Therapeutics INC | $16.21 | 2021 | |
| Travere Therapeutics, INC. | $16.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.